Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continuous Regorafenib in Refractory GIST
NCT02889328Phase 2Completed
- Sponsor
- Asan Medical Center
- Start
- Sep 2016
- Primary completion
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of regorafenib in gastrointestinal stromal tumor (GIST), sponsored by Asan Medical Center. Started Sep 2016; status: completed.
02
Drugs
regorafenib
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NCT02889328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02889328.